Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

22nd Century Group Inc XXII

22nd Century Group, Inc. is an agricultural biotechnology company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. Additionally, the Company provide contract manufacturing services for conventional combustible tobacco products for third-party brands. The Company operates through a single segment named Tobacco. Its tobacco segment is engaged in contract manufacturing organization (CMO) customer contracts that consist of obligations to manufacture the customers' branded filtered cigars and cigarettes. The tobacco segment is engaged in the sale of its reduced nicotine content (RNC) cigarettes, sold under the brand name VLN, or research cigarettes sold under the brand name SPECTRUM. It uses plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products.


NDAQ:XXII - Post by User

Post by martelon Sep 24, 2024 9:33am
30 Views
Post# 36238043

$XXII Pioneering a New Era in Tobacco Products

$XXII Pioneering a New Era in Tobacco Products

22nd Century Group, Inc. ($XXII) is gaining recognition as an innovative force in the tobacco industry, particularly with its flagship product, VLN® cigarettes. These cigarettes are the first and only combustible tobacco product to receive the Modified Risk Tobacco Product (MRTP) designation from the U.S. FDA, setting them apart as a safer alternative. Designed with 95% less nicotine than traditional cigarettes, VLN® targets adult smokers seeking to reduce nicotine consumption or quit altogether. This positions 22nd Century as a leader in the growing market for harm-reduction products.

With a strong focus on public health, 22nd Century’s mission—"to sell the last cigarette before the 22nd Century"—underscores its commitment to harm reduction and sustainable business practices. This strategy resonates in a market that is increasingly focused on safer smoking alternatives, regulatory changes, and the future of nicotine products.

Despite these advancements, the stock (XXII) has been highly volatile, reflecting market uncertainty. In the past year, the stock has fluctuated significantly, impacted by broader market conditions and company-specific news. Investors will be watching closely to see how 22nd Century capitalizes on its innovative products and whether it can maintain momentum in an evolving industry.

<< Previous
Bullboard Posts
Next >>